BDP5290

1817698-21-7

C17H18ClN7O

DMSO : 12.5 mg/mL (33.62 mM; Need ultrasonic)

TGF-beta/Smad; Stem Cell/Wnt; Cell Cycle/DNA Damage

BDP5290 is a potent inhibitor of both ROCK and MRCK with IC₅₀s of 5 nM, 50 nM, 10 nM and 100 nM for ROCK1, ROCK2, MRCKalpha and MRCKbeta, respectively. IC50 & Target: IC50: 5 nM (ROCK1), 50 nM (ROCK2), 10 nM (MRCKalpha), 100 nM (MRCKbeta)^[1] In Vitro: The K_i of BDP5290 for MRCKalpha is 10 nM, which is slightly more than the K_i of 4 nM for MRCKbeta. 3 uM BDP5290 completely inhibits myosin II light chain (MLC) phosphorylation induced by MRCKbeta, but not by ROCK1 or ROCK2. At higher concentrations, BDP5290 reduces MLC phosphorylation (pMLC) to undetectable levels. BDP5290 reduces MDA-MB-231 invasion at all tested concentrations starting from 0.1 uM, with virtually complete inhibition at 10 uM. After 24 hours in the presence of BDP5290 cell viability is slightly reduced with an EC₅₀ ?>10 uM. Wound closure is inhibited by?>60% at 1 uM BDP5290, a concentration that has no effect on cell viability^[2].